Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma

Condition:   Asthma
Interventions:   Drug: FP 100mcg BID plus GSK2190915 100mg QD (AM);   Drug: FP 100mcg BID plus GSK2190915 300mg QD (AM);   Drug: FP 100mcg BID plus montelukast 10mg QD (PM);   Drug: FP 100mcg BID plus placebo BID;   Drug: FP/SAL 100/50mcg BID plus placebo BID
Sponsor:   GlaxoSmithKline
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Leave a Reply

Your email address will not be published. Required fields are marked *